



دانشگاه علوم پزشکی و خدمات  
بهداشتی درمانی تهران

مرکز قلب تهران

thc.tums.ac.ir  
**12**  
th

**Annual Tehran Heart  
Center Congress**

**7th CRITICAL CARDIOVASCULAR CARE**

**دوازدهمین کنگره سالیانه مرکز قلب تهران**

**2025**

۲۵ و ۲۶ بهمن ماه ۱۴۰۳

**13 & 14 February  
Tehran Heart Center  
Tehran, Iran**

# Management of stent thrombosis

# Management of stent thrombosis

**Maryam Mehrpooya MD,**  
Associate professor of cardiology

Fellowship of Interventional Cardiology  
Tehran university of medical science  
Imam Khomeini Hospital

# Nightmare for cardiologist



**Panel B: Complication of Coronary intervention**

**Moderator: Dr. Haji Zeinali**

**Panelists: Dr. Amirzadegan, Dr. Eslami, V, Dr. Taghavi, Dr. Khalilpour, Dr. Ghorbanzadeh**

**9:30 -10:15**

Stent thrombosis management	<b>Dr. Mehrpouya</b>
Coronary dissection & perforation management	<b>Dr. Moezi</b>
No reflow & slow flow management	<b>Dr. Rouzi Talab</b>

10:15 - 10:45

Break

# Introduction

- ❖ **An important cause of acute MI is stent thrombosis**
- ❖ **Primary PCI for stent thrombosis is less effective (76%–80% successful reperfusion) than primary PCI for native artery occlusion**
- ❖ **STEMI caused by stent thrombosis is also associated with an increased risk for long-term MI (23%) and repeat stent thrombosis (15%) compared with STEMI caused by native artery occlusion**

STATE-OF-THE-ART REVIEW

# Stent Thrombosis

## A Clinical Perspective

Bimmer E. Claessen, MD, PhD,\* José P.S. Henriques  
 Roxana Mehran, MD,†§ Jan J. Piek, MD, PhD,\* Geert

**TABLE 1 Definition of Stent Thrombosis According to the Valve Academic Research Consortium**

Level of Certainty	Timing
<b>Definite</b>	<b>Early</b>
Angiographic or pathological confirmation of partial or total thrombotic occlusion within the peri-stent region  AND at least 1 of the following additional criteria: Acute ischemic symptoms Ischemic electrocardiogram changes Elevated cardiac biomarkers	Acute (<24 h)  Subacute (24 h to 30 days)
<b>Probable</b>	<b>Late</b>
Any unexplained death <30 days of stent implantation  Any myocardial infarction related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause	31 days to 1 yr
<b>Possible</b>	<b>Very Late</b>
Any unexplained death beyond 30 days	>1 yr


# Introduction

**An Intraprocedural stent thrombosis (IPST) and acute stent thrombosis (<24 hours from implantation) *are rare events, occurring 0.8% to 1.2% and 0.1% to 0.9% of cases, respectively***

**TABLE 3 Predictors of Early and (Very) Late Stent Thrombosis**

	<b>Early Stent Thrombosis</b>	<b>(Very) Late Stent Thrombosis</b>
Patient	Malignancy, heart failure, peripheral artery disease, diabetes mellitus, acute coronary syndromes, nonadherence to dual-antiplatelet therapy, genetic polymorphisms, thrombocytosis	End-stage renal disease, smoking, STEMI, nonadherence to dual-antiplatelet therapy (unknown for very late ST)
Lesion	Bifurcation lesion, LAD, vessel size, lesion length, thrombus, saphenous vein grafts	LAD, incomplete endothelialization, delayed healing, previous brachytherapy, vein graft stenting
Procedural	Stent undersizing, stent underexpansion, stent malapposition, dissection, no pre-procedural thienopyridine administration, bivalirudin as anticoagulant in STEMI patients, stent length	DES (compared with BMS), permanent polymer DES (compared with bioresorbable polymer DES), overlapping DES
Post-procedural	Discontinuation of antiplatelet therapy	Discontinuation of antiplatelet therapy (unknown for very late ST), late acquired stent malapposition










# Treatment for ST and the role of intravascular imaging

# Prevention


- ❖ **Avoiding stent thrombosis requires operators to be meticulous about anticoagulation and stent implantation**
- ❖ **A fundamental axiom is confirming adequate outflow prior to stent implantation**
- ❖ **Placing a stent in an artery with no-reflow due to microvascular obstruction or a vessel with poor distal runoff is risky and may increase the likelihood of stent thrombosis**

# Procedural Mechanisms of ST







Incomplete  
stent apposition



Stent  
underexpansion



Edge  
dissection



# Baseline



# Follow-up

A


*Baseline incomplete stent apposition*



**Incomplete Stent apposition**




**Resolved**  
Incomplete apposition




**Persistent**  
Incomplete apposition

B


*Late-acquired incomplete stent apposition*



**Complete Stent apposition**



**Late-acquired**  
Incomplete apposition  
(Thrombus dissolution)




**Late-acquired**  
Incomplete apposition




I. Incomplete stent apposition due to positive vessel remodeling




II. Incomplete stent apposition due to thrombus dissolution




III. Incomplete stent apposition due to stent underexpansion









Under-expansion




Malapposition



Edge dissection



Neo-atherosclerosis



- ❖ (Top) The axial image shows an OCT catheter in the center of RCA artery
- ❖ At the 2-o'clock position, bright, reflective stent struts are visualized and are not in contact with the intima of the artery (*blue dotted arrow*)
- ❖ There is a gap of 0.6 mm between these stent struts and the artery
- ❖ This finding indicates *stent malapposition*, a mechanical, stent-based risk factor for late stent thrombosis

## Neoatherosclerosis as a Cause of Very Late Stent Thrombosis of a DES Placed in an SVG


- ❖ Three years after DES placement to the distal body of an SVG to the RCA, this patient presented with unstable angina
- ❖ SVG angiography revealed a severe, hazy filling defect in the SVG stent
- ❖ He was placed on IV heparin
- ❖ The following day, OCT of the SVG was performed
- ❖ Two sequential OCT frames are presented with full and magnified images (dotted white box regions)

OCT of the stent reveals mild neointima within the stent, but at the 4-o'clock position, there is evidence of cap disruption and a residual crater (white arrowhead,

➤ (Bottom) In the adjacent OCT frame, the same region *at the 4-o'clock position demonstrates an irregular contour consistent with thrombus within the stent*


➤ Stent struts are noted covered by neointima (small arrowheads at the 2-o'clock position)

➤ These findings indicate plaque rupture of neoatherosclerosis within a stent, a recently appreciated mechanism of stent thrombosis



# Treatment

- ❖ When confronted with acute or IPST, one must be very prompt at restoring perfusion to minimize myocardial damage and the approach to treatment should include both pharmacologic and mechanical optimization
- ❖ Certainly, if intracoronary thrombus develops, ***prompt aspiration thrombectomy or angioplasty*** should be performed immediately to restore patency
- ❖ ***Therapeutic anticoagulation*** should be confirmed and more potent antiplatelet therapy considered, as both ***IV cangrelor and glycoprotein inhibition*** were both associated with less IPST.



*Stent thrombosis*

- Antiplatelet drug check
- Consider onset timing

**Urgent PCI**



*Guidewire advancement and angiographic evaluation*

- High thrombus amount → TA and/or i.c. GPIIb/IIIa inhibitors
- Low thrombus amount → i.v cangrelor (in P2Y12 inhibitor naive patients)

Obtain vessel patency and adequate flow

**Index procedure or second staged procedure**  
(if patient's conditions do not allow further investigations during index PCI)



*Identify the mechanism*

IVI and/or stent enhancement techniques

- Stent-related issues [ Underexpansion, Malapposition, Fracture ]
- Procedure-related issues [ Edge dissection, Plaque missing, Plaque protrusion ]
- In-stent restenosis [ Neointimal hyperplasia, Neointimal hyperplasia ]

**Individualized treatment**

# Treatment

- ❖ **Bailout glycoprotein inhibitor, loading with either prasugrel or ticagrelor, or switching to cangrelor to rapidly reach maximal steady state platelet inhibition may be helpful if not already using these medications**
- ❖ **If there is suspicion the patient could have heparin-induced thrombocytopenia (HITT), switching to a direct-thrombin inhibitor such as bivalirudin should be considered**
- ❖ **Intravascular imaging with either IVUS or OCT should be used to determine stent apposition, expansion, and presence of edge dissections**

# Treatment

- ❖ **Optimization of stent deployment with appropriate postdilation and treatment of edge dissections with additional stents will be imperative to prevent repeat stent thrombosis**
  
- ❖ **Additional stent implantation should be done judiciously because each millimeter of stent increases the probability of IPST**

# Thrombectomy

~~Mechanical~~



~~Rheolytic thrombectomy (AngioJet)~~

Aspiration



Export

Pronto



Penumbra Through guide/guide extension








Export      Export Advance      Priority one      Quick cat      Express way      Fetch 2      Pronto LP      Pronto V3      Pronto V4

**Bavry T. Cardiovascular Intervention: A Companion to Braunwald's Heart Disease 2015**



# Procedural Mechanisms of ST

- ❖ Stent underexpansion
- ❖ Stent malapposition
- ❖ Dissections
- ❖ New plaque rupture
- ❖ Stent fracture
- ❖ Negative remodeling at the stent edge
- ❖ Neoatherosclerosis

# Procedural Mechanisms of ST

## ❖ Stent underexpansion:

- If confirmed by IVUS/OCT, high-pressure balloon angioplasty with noncompliant balloons sized according to the normal adjacent reference segment can be attempted
- A new stent can be particularly deleterious in treating stent underexpansion if the reason is due to a highly rigid (e.g., calcified) segment because multiple layers of stent metal will be present in an underexpanded lesion
- If balloon expansion is ineffective, then the patient should be temporarily treated with balloon angioplasty and return for definite therapy after the acute ST presentation has

# Procedural Mechanisms of ST

## ❖ **Stent malapposition :**

- This can be verified by the existence of a space filled with blood between the stent struts and the vessel wall
- The extent of this low-flow area has been associated with ST
- Angioplasty with an appropriately sized balloon as determined by the IVUS/OCT-derived measurement of the arterial wall diameter at the culprit cross sections typically suffices to ameliorate this problem

❖ **Dissections :** Stent edge dissections can provoke ST and are easily detectable by IVUS/OCT, despite being sometimes dubious angiographically. A new stent can typically cover them and restore adequate

❖ **New plaque rupture:** This condition essentially means the absence of ST per se and supports the extension of thrombosis within the stent after initiation at the adjacent plaque disruption area. A new stent may be needed to treat the culprit new lesion area.

# Procedural Mechanisms of ST

## ❖ Stent fracture :


- RCA lesions, excessive tortuosity or angulation of the vessel, overlapping stents, and longer stents have been associated with an increased risk of stent fracture
- A stent fracture may cause mechanical damage to the endothelium that could subsequently lead to ST and can be treated with implantation of a short stent to cover the area of the stent fracture.

## ❖ Negative remodeling at the stent edge


This can explain abrupt lumen compromise distal to a stent that might have predisposed to flow reduction

## ❖ Neoatherosclerosis


The development of an ACS caused by rupture or erosion of a neoatherosclerotic plaque in a previously stented lesion has been acknowledged as a potential culprit in very late ST



## Suggested algorithm for management of abrupt closure



# STENT THROMBOSIS



**Figure 6.**  
 SCAI algorithmic approach to stent thrombosis.



# Take home messages

- ❖ A comprehensive approach encompassing precise diagnosis, urgent procedural interventions, and tailored pharmacological treatments is essential for optimizing patient outcomes during ST
- ❖ Intracoronary antithrombotic therapies combined with TA and IVI guidance play pivotal roles in achieving optimal outcomes, particularly in cases with a high thrombus burden and complex stent-related issues
- ❖ When ISR or ST is encountered, imaging should be strongly considered to optimize the subsequent approach to these challenging cases.



دانشگاه علوم پزشکی و خدمات  
بهداشتی درماني تهران

مرکز قلب تهران



[thc.tums.ac.ir](http://thc.tums.ac.ir)